🧬The power of big data to advance genomics into clinical care🧬 The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response. Click on the link in the comments to read more! 👇 #genomics #precisionmedicine #personalisedmedicine
Drug Target Review
Book and Periodical Publishing
Brasted, Kent 17,577 followers
Your gateway to the drug discovery industry
About us
Drug Target Review, published quarterly, provides a voice for the drug discovery industry, promoting the latest research and developments, funding projects, and cutting-edge technological developments. We support academia, campus companies, tech transfers, research facilities and Pharma by creating a community with the goal of educating and sharing information and news. This community of diverse individuals is able to keep up to speed with research, news and funding as it happens through print, online and workshops. SUBSCRIBE FOR FREE TODAY. http://bit.ly/2H0MBSQ
- Website
-
http://www.drugtargetreview.com/
External link for Drug Target Review
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Headquarters
- Brasted, Kent
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Assays, Drug Targets, Omics Sciences, Stem Cells, Hit-to-lead, Imaging, Personalised Medicine, Screening, Biomarkers, Microbiota, Microfluidics, Kinases, Antibodies, Mass Spectrometry, Protein Expression, Enzymes, Proteomics, Flow Cytometry, RNA, and Drug Discovery
Locations
-
Primary
Court Lodge
Hogtrough Hill
Brasted, Kent TN16 1NU, GB
Employees at Drug Target Review
Updates
-
🔊 Weekly round-up! 🔬 Translating ‘nature’s cues’ into breakthrough immunotherapies Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri Ph.D., Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming to improve efficacy and minimise adverse effects. 👩🔬 Women in STEM with Juliet Williams We spoke to Juliet Williams, Head of Research at Kymera Therapeutics. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver results in previously undruggable conditions. 🐁 New model offers a unique method to study Parkinson’s disease Researchers at Weill Cornell Medicine have shown that mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models. 💊 The role of KDR in the survival of HTLV-1-infected T cells Researchers at Penn State College of Medicine have discovered that KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1. Click on the links in the comments to read more! 👇 #drugdiscovery #lifescience #drugtargets
-
-
💻 Have you registered for our upcoming webinar with Eurofins DiscoverX? 📅 Now's the time! Head this way to register >> https://bit.ly/3VLUEKG to hear more from Terry Kenakin and discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules. We'll see you there! #Assay #DrugDiscovery #GPCR
-
-
Just launched 🚀 💻 Join our webinar with Eurofins Discovery to discover the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines During this webinar, Shantanu Roychowdhury will: ✅ Discuss how DiscoverX is developing new cell lines with CRISPR™ technology ✅ Understand the role and significance of ADME permeability assays ✅ Explore drug-drug interactions and how we test for them ✅ Discover how proteomics is reshaping the drug development market Register a place here: https://bit.ly/46dm019 #CRISPR #druginteration #Eurofins #celllines #proteomics
-
-
💻Part three: pragmatic guidelines to getting the best out of LLMS💻 There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs. Click the link in the comments to read more! 👇 #LLM #drugdiscovery #AI
-
-
📩 Open for the latest in the drug discovery industry! This week find out more about... 👉 How ChatGPT enriched animal study results 👉 The potential of lab-grown recombinant polyclonal antibodies 👉 The transformative potential of liquid biopsy in oncology drug development 👉 Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma. 👉 Small molecule inducers of trained immunity 💻 Don't miss out on registered for our new webinar with Eurofins Discovery! #AI #Tumour #Oncology #DrugDiscovery
-
Today is #WorldBrainDay! 🧠 Read all about the latest pioneering research that could revolutionise brain health 👇 🧫Brain organoids: a fascinating and powerful tool for drug discovery By mimicking the function of the human brain, in both health and disease, organoid application in drug discovery holds significant potential for identifying new treatments for brain disorders, explains Francesca Cavallo from Sygnature Discovery. https://bit.ly/3zNDoNI 💻 Capturing the computational abilities of real neurons Researchers at the Flatiron Institute’s Center for Computational Neuroscience (CNN) have developed a new neural network computational model that more closely reflects the abilities of real neurons in the human brain, which could greatly advance artificial intelligence (AI) progress. https://bit.ly/3L3Sm4C 🧠 Elucidating the pathophysiology of migraines Scientists at the University of Copenhagen (Københavns Universitet), Rigshospitalet and Bispebjerg Hospital are the first to show that proteins released from the brain during migraine with aura are transported with cerebrospinal fluid (CSF) to pain-signalling nerves, causing severe headaches. The new study offers promise for the development of new treatments for migraines. https://bit.ly/4bWn4rx 🧪Identifying biomarkers for progressive supranuclear palsy Researchers at University of California, San Francisco discovered a method to identify progressive supranuclear palsy (PSP), a mysterious and fatal neurological disorder, while patients are still alive. Using a novel high-throughput technology, the identification of protein biomarkers in spinal fluid could result in a diagnostic test and targeted therapies. https://bit.ly/3WceFdD #WorldBrainDay #neurological #drugtargets
-
-
🔊 Latest news! 🧬Prime editing corrects the CFTR gene mutation Scientists at the Broad Institute of MIT and Harvard and the University of Iowa have developed a gene-editing method that corrects the most common mutation causing cystic fibrosis. This could lead to treatments that are administered only once and have fewer side effects. Go to our website to read more! 👉 https://lnkd.in/enDQRQGX #cysticfibrosis #primeediting #mutation
-
-
💊Which drug delivery system is the most promising for cancer treatment?💊 #drugdelivery #cancer #liposomes
This content isn’t available here
Access this content and more in the LinkedIn app
-
📢 Join our webinar with Eurofins Discovery on 4th September at 4:00pm BST 💻 ✅Discover some new offerings for evaluation of P-gp and BCRP drug interactions with cell lines developed with CRISPR™ technology. ✅ Plus, we will highlight the development, generation and characterisation of both knock-out and knock-in MDCKII cell lines, as well as evaluation of reference pharmacology for use in drug discovery and regulatory applications. Plus, hear from our speaker Shantanu Roychowdhury - Group Leader- ADME-Tox- Eurofins Discovery 🖱 Click to register your place here: https://bit.ly/4bPHClh Invite along anyone who might be interested! #CRISPR #newwebinar #druginteraction #drugdiscovery
This content isn’t available here
Access this content and more in the LinkedIn app